Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Boosting immune responses against leukaemia

Boosting immune responses against leukaemia

In the first of its kind, a translational study undertaken at the Malaghan Institute of Medical Research has revealed that boosting the activity of a rare type of immune cell could be an effective way to vaccinate patients with chronic lymphocytic leukaemia (CLL) against their own cancer.

CLL is the most common blood cancer in New Zealand. The prevalence of CLL increases with age, reaching 1 in 400 in individuals over 70 years old. Although many people with CLL never need treatment, a significant number of patients are diagnosed at a young age or have aggressive disease, exhausting conventional therapies.

Haematologist Dr Robert Weinkove says that bone marrow transplantation is the only curative treatment for CLL and involves replacing the immune system of patients with that of a matched donor.

“Part of the reason that bone marrow transplants work is that the new (donor) immune system recognises the leukaemia cells as foreign and destroys them,” says Dr Weinkove. “This is a good demonstration of how immune therapies can successfully cure established cancers in humans.”

Bone marrow transplants are not without their problems however. Not all patients find a donor; patients are prone to infections for months or even years afterwards; and the treatment itself can be so toxic that it is not suitable for many patients.

“To identify more targeted, low risk immune therapies, we focused on a rare type of immune cell called invariant natural killer T (iNKT) cells,” says Dr Weinkove.

Previous research at the Malaghan Institute and overseas has shown that iNKT cells can be activated by a compound called alpha-galactosylceramide (alpha-GalCer), which was first found in a Japanese marine sponge. This leads to significantly enhanced tumour-specific immune responses.

While iNKT cells are promising targets for immunotherapies, in many cancer patients iNKT cell numbers are either reduced, or the cells do not work properly. Since iNKT cells had never been characterised in patients with CLL before, Dr Weinkove launched a collaborative study between the Wellington Hospital Blood and Cancer Centre and the Malaghan Institute, to determine the number, phenotype and function of iNKT cells in people with this form of leukaemia.

Between 2008 and 2011, Dr Weinkove collected blood samples from 40 patients with CLL and from 30 healthy volunteers of a similar age, from the greater Wellington region. He then undertook a series of laboratory tests to compare the number and function of the iNKT cells from these individuals.

This study, which has recently been published in the open-access, international scientific journal Haematologica, constitutes the first comprehensive investigation of iNKT cell numbers and function in patients with CLL.

“We found that we could detect and isolate iNKT cells from individuals with CLL, and that these cells were able to respond to alpha-GalCer,” says Dr Weinkove. “This is important because it suggests that iNKT cells remain functional in these patients, and that targeting them with treatments like alpha-GalCer might be a way of enhancing their ability to drive anti-cancer immune responses.”

Having shown such great promise in the laboratory, the next step will be to see if these results can be replicated in patients.

“Designing and running safe clinical trials is a major undertaking, but we are exploring a number of ideas, including the possibility of giving alpha-GalCer to patients with blood cancers to boost their immune responses,” says Dr Weinkove.

This work complements the dendritic cell cancer vaccination programme at the Malaghan Institute, further details of which are available at www.malaghan.org.nz.

This research was supported by grants from the Leukaemia & Blood Foundation, Genesis Oncology Trust and NZ Lottery Grants Board. Dr Weinkove also received support from a Genzyme New Investigators Scholarship through the Haematology Society of Australia and New Zealand.
ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Auckland Port Study: Port To Ship Out – No Departure Date

Interest groups in Auckland and its waterfront chose a group of representatives to determine the future of the port. Their consensus is that the Port is going to have to move but not before a credible location is confirmed... More>>

ALSO:

Tax: GST Threshold For Online Purchases Won't Lower Before 2018

The government wants to lower the threshold on online purchases which qualify for GST from mid-2018, but says more work is needed and there will be no change without public consultation. More>>

ALSO:

North Canterbury: Government Extends Drought Classification

The government has extended a drought classification for the eastern South Island until the end of the year, meaning the area will have officially been in drought for almost two years, the longest period for such a category. More>>

ALSO:

Negotiations Fail: Christchurch Convention Centre Build To Proceed Without PCNZ

After protracted negotiations, the government has ditched the construction consortium it picked to build Christchurch's replacement convention centre, which it now anticipates delivering at least two years behind the original schedule. More>>

ALSO:

Other Centres' Convention Centres:

Ruataniwha: Greenpeace Launches Legal Challenge Against $1b Dam Plan

Greenpeace NZ is launching a legal challenge against a controversial plan to build a dam that’s set to cost close to $1 billion and will pollute a region’s rivers. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news